Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Company Fined After Worker Suffers Fatal Injuries After Being Run Over At Work, UK
The Health and Safety Executive (HSE) is urging companies to ensure that sufficient safety procedures and risk assessments are in place to properly protect staff.
generic viagra online
Low Blood Glucose Levels Do Not Explain Excess Deaths In Accord Trial
Low blood glucose levels do not explain the excess deaths seen in the intensive control group of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, according to a report presented here today at the American Diabetes Association"s 69th Scientific Sessions.
News of the day
Environmental Cues Control Reproductive Timing And Longevity, University Of Minnesota Study Shows
When humans and animals delay reproduction because food or other res are scarce, they may live longer to increase the impact of reproduction, according to a new study by University of Minnesota researchers published in the June 25 issue of PLoS (Public Library of Science) One.
Health Insurance

BioAlliance Pharma Obtains European Approval For Loramyc(R) Tablet Embossing And Extension Of Its Shelf Life To 36 Months

BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on therapy and supportive care in cancer and AIDS, announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis. The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance Pharma submitted a new drug application for Loramyc® to the Food and Drug Administration (FDA) in June 2009. BioAlliance Pharma will be able to harmonize Loramyc® production within those two key markets. BioAlliance Pharma also received European approval for extension of Loramyc®"s shelf life from 18 to 36 months. These two key industrial parameters are complementary assets for Loramyc® and will help optimizing manufacturing, storage and distribution costs. BioAlliance Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009